There’s now concerted effort to reduce emissions in the cell therapy supply chain. Reducing CO2 emissions can drive efficiency in supply chains, increasing the profitability and sustainability of business models, and help remove redundancy in cell therapy shipping and manufacturing processes.
Cold-chain logistics is one of the most carbon-intensive aspects of cell therapy manufacturing. Cytiva has shown that switching to a liquid nitrogen-free (LN2-free) cryopreservation process can reduce CO2 emissions by 87%, and cooling costs by > 95%.
This application note considers shipments within the cell therapy workflow, from initial patient sample to final cell therapy arrival at the patient’s side. Review how the VIA Capsule™ shipper helps reduce costs and carbon footprint for cell therapies.
By streamlining the delivery processes with efficiency-led design and smart logistics, manufacturers can reduce the financial costs of transport and CO2 burden by 57%. The VIA Capsule™ shipper’s smart disinfection design reduces the number of required shipments for any given cell therapy manufacturing process.